Gut Microbiota Characteristics in Acute Pancreatitis Patients and Their Association with SIRS and Organ Failure: An Experimental Study

急性胰腺炎患者肠道菌群特征及其与全身炎症反应综合征和器官衰竭的关系:一项实验研究

阅读:1

Abstract

BACKGROUND: Acute pancreatitis (AP) is a common gastrointestinal disease. Systemic inflammatory response syndrome (SIRS), a severe complication of AP, increases the risk of organ failure and progression to severe AP (SAP). Gut microbiota dysbiosis is linked to AP pathogenesis. The aim of this study is to investigate the gut microbiota characteristics of AP patients and their association with SIRS and organ failure. METHODS: Rectal swabs from 19 healthy controls (HC) and 88 AP patients (stratified into non_SIRS, SIRS, low/med/high_sequential organ failure assessment (SOFA) groups) were analyzed using 16S rRNA gene sequencing. Microbiota diversity, composition, and function were evaluated, and random forest diagnostic models were constructed. RESULTS: Compared with HC, AP (SIRS/non_SIRS) patients had altered clinical indices, reduced gut microbial richness and diversity. As SOFA scores increased, the high_SOFA group exhibited further reductions in richness and diversity. Barplots analysis showed that there were differences in the mainly dominant microbiota between HC and AP (SIRS/non_SIRS) patients. Some differentially abundant genera such as Faecalibacterium, Parabacteroides, Megasphaera, and Fusicatenibacter may be closely associated with the occurrence of AP, development of SIRS, and severity of organ failure. Furthermore, functional pathways like L-isoleucine biosynthesis, lysine biosynthesis, AMPK signaling, and glycogen biosynthesis may also play significant roles in diseases. The random forest models constructed for distinguishing between HC and non_SIRS, as well as for distinguishing between HC and SIRS, showed extremely diagnostic accuracy. CONCLUSION: Gut microbiota dysbiosis is correlated with the occurrence of AP, development of SIRS, and severity of organ failure. Specific microbiota taxa and functional pathways may serve as potential therapeutic targets or diagnostic biomarkers for AP, providing a microbial perspective for personalized management of this disease.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。